Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. Clinicoecon Outcomes Res 2019;11:431-439
Date
08/15/2019Pubmed ID
31410040Pubmed Central ID
PMC6643051DOI
10.2147/CEOR.S207127Scopus ID
2-s2.0-85071581040 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
PURPOSE: Cardiac dysfunction is common in amyloid light-chain (AL) amyloidosis, a rare disease caused by extracellular deposition of misfolded immunoglobulin light chains. This study aimed to examine economic/clinical disease burden in hospitalized cardiac amyloidosis patients.
PATIENTS AND METHODS: Cardiac amyloidosis patients ≥18 years old hospitalized between 2014 and 2016 were identified in claims if they had ≥1 inpatient claim consistent with amyloidosis and evidence of cardiac dysfunction. Descriptive statistics were reported.
RESULTS: 3239 cardiac amyloidosis patients [1795 (55.4%) with concurrent renal disease] were identified. Mean (SD) length of stay was 8.3 (11.1) days. 25.2% were admitted to the intensive care unit. Mean overall hospitalization costs were USD$20,584. In-hospital mortality was 9.0% overall. 16.8% were readmitted within 30 days, with 11.2% dying in-hospital and a mean readmission cost of USD$18,536.
CONCLUSION: Hospitalization for cardiac amyloidosis is costly, with high rates of readmission and mortality. Opportunities exist to improve care.
